Bibliometric analysis reveals growing research on cutaneous immune-related adverse events, indicating a shift in focus.
With the widespread use of immune checkpoint inhibitors (ICIs) in cancer treatment, cutaneous immune-related adverse events (cirAEs) have attracted increasing attention. This bibliometric analysis reveals that research on cirAEs has grown steadily, with enhanced global collaboration. The focus has progressively shifted from early studies on specific agents and conditions toward severe cutaneous adverse reactions, diverse cancer types, and systemic clinical management strategies. This evolution reflects a deeper investigation into underlying mechanisms and a heightened emphasis on personalized treatment approaches, thus offering insights for future interdisciplinary research aimed at optimizing clinical management and improving treatment safety.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: